Drug Trial Radar · NCT02755064
Relationship Between Gastric Emptying and Glycemic Variability in Type 1 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Apr 28, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jun 2010
Primary completion
Nov 2013
Study completion Nov 2013
Sponsor
- Lead sponsor
- Adil BharuchaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Basic science
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
With this study, the investigators hoped to learn if the rate at which food empties from the stomach affects blood sugar values. Using data from this study, we hope to improve our ability to control blood sugars in individuals with type 1 diabetes mellitus.
Conditions
- Diabetes Mellitus, Type 1
Interventions
Erythromycin lactobionateDrug
In Phase 1 of the study, during the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. Thereafter, an infusion of 1.5 or 2.5 mg/kg was given over the next 50 min with the same infusion pump. The goal of testing 2 different doses was not to assess dose-related effects but to compare glycemic indices against a spectrum of gastric emptying rates.
Placebo IVDrug
In Phase 1 of the study, during the second visit, saline was given as an initial bolus over 10 min immediately before the meal. Thereafter, an infusion of saline was given over the next 50 min with the same infusion pump.
[13C]-SpirulinaDrug
The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
Erythromycin Ethylsuccinate SuspensionDrug
In Phase 2 of the study, subjects randomized to this arm will receive Erythromycin Ethylsuccinate Suspension 250 mg tid orally for a total period of 7 days.
Placebo SuspensionDrug
In Phase 2 of the study, subjects randomized to this arm will receive an oral placebo prepared to mimic the Erythromycin Ethylsuccinate Suspension for a total period of 7 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relationship between gastric emptying and glycemiaTime frame: 11 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.